Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Medicine and Dentistry

• Programmed Death-Ligand 1 100%
• Marker 83%
• Patient Selection 66%
• Biological Marker 66%
• Immunotherapy 33%
• Lung Cancer 33%
• Combination Therapy 33%
• Immunohistochemistry 33%
• Programmed Death 1 Receptor 33%
• Cells 33%
• Clinical Trial 33%
• Clonal Variation 16%
• Protein 16%
• Homeostasis 16%
• Monotherapy 16%
• Treatment Response 16%
• Somatics 16%
• Nodular Melanoma 16%
• Clear Cell Renal Cell Carcinoma 16%
• T Lymphocyte Receptor 16%
• Cancer Therapy 16%
• Solid Malignant Neoplasm 16%
• Tumor Microenvironment 16%
• Receptor Protein 16%
• CTLA-4 16%
• Protein Ligand 16%
• Patient 16%
• Assay 16%
• Therapeutic Procedure 16%
• Comprehension 16%
• Consensus 16%
• T Cell 16%

INIS

• patients 83%
• biological markers 66%
• cancer 50%
• proteins 50%
• clinical trials 33%
• tumors 33%
• therapy 33%
• receptors 33%
• values 33%
• immunotherapy 33%
• lung cells 33%
• apoptosis 33%
• solids 16%
• balances 16%
• dynamics 16%
• kidneys 16%
• homeostasis 16%
• inhibition 16%
• utilities 16%
• optimization 16%
• antigens 16%
• ligands 16%
• lymphocytes 16%
• melanomas 16%
• carcinomas 16%